Fluid biomarkers in primary tauopathies

项目总结 在过去的几年里，准确检测阿尔茨海默病(AD)大脑的血液生物标志物 病理学已经发展起来了。然而，没有特定的液体或成像生物标记物可用于原发肿瘤 包括进行性核上性瘫痪(PSP)、皮质基底膜变性(CBD)和 额颞叶变性(FTLD)。我们最近在脑脊液中发现了特定种类的tau。 体液(CSF)，可从健康对照组和其他体感疾病中识别出原发肌萎缩症的亚组 具有中等的特异性和敏感度。在这项研究中，我们建议优化质谱学方法，以 更好地区分脑脊液中的原发性变态反应。在新方法的基础上，我们将把这些主要的 血液中的生物标记物，并测试它们是否与配对脑脊液中的生物标记物测量相关。本研究 将提供血液中原发变态反应的第一个测量方法，并准备进行大型队列研究 原发变态脑脊液和血液以区分原发变态或变态的亚型 神经或精神疾病。如果血液生物标记物被开发出来，它很可能会被广泛使用，并可能 促进原发脊椎病的研究和诊断。

Project summary Over the past several years, blood-based biomarkers that accurately detect Alzheimer’s Disease (AD) brain pathology have been developed. However, there are no specific fluid or imaging biomarkers for primary tauopathies including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal lobar degeneration (FTLD). We have recently identified specific species of tau in cerebrospinal fluid (CSF) that can identify subsets of primary tauopathies from healthy control groups and other tauopathies with moderate specificity and sensitivity. In this study, we propose to optimize mass spectrometry methods to better distinguish primary tauopathies in CSF. Based on the new methods, we will translate these primary tauopathy biomarkers to blood and test if they correlate with the biomarker measures in paired CSF. This study will provide first measures of primary tauopathies in blood and prepare for large cohort studies looking into primary tauopathy CSF and blood to distinguish subgroups of primary tauopathies or tauopathies from other neurological or psychiatric diseases. If blood biomarkers are developed, it will likely be widely used and could facilitate primary tauopathy research and diagnoses.